Results 121 to 130 of about 260,112 (235)

MDR TB Trends in US [PDF]

open access: yesInfection Control & Hospital Epidemiology, 1998
Gina Pugliese, Martin S. Favero
openaire   +1 more source

Characteristics of MDR-TB cohort.

open access: yes, 2018
Characteristics of MDR-TB cohort.
Malik M. Parmar (5088815)   +6 more
core   +1 more source

Examples of MDR TB care cascades.

open access: yes, 2019
(A) The care cascade for individuals with MDR TB in India in 2013, modified from [10] based on updated WHO MDR TB incidence estimates [23], and (B) the care cascade for individuals with rifampin-resistant TB in South Africa in 2013 [11].
Vineet K. Chadha (292177)   +6 more
core   +1 more source

MDR TB-The Lethal Sound of Silent Mutations

open access: yesJournal of the College of Physicians and Surgeons Pakistan
Null.
openaire   +2 more sources

Treatment outcomes of patients with Multidrug-Resistant Tuberculosis (MDR- TB) compared with Non-MDR-TB infections in peninsular malaysia

open access: yes, 2016
Background: Treating patients with multidrug-resistant tuberculosis (MDR-TB) strains is more complicated, complex, toxic, expensive, than treating patients with susceptible TB strains.
Azhanie Sardangi
core  

MDR TB - When the Xpert Fails [PDF]

open access: yesTP99. TP099 CURIOUS MYCOBACTERIAL CASES AND MIMICKERS, 2021
C. Gill   +10 more
openaire   +1 more source

Multidrug resistant tuberculosis (MDR-TB) in Eritrea: a retrospective cohort analysis of mortality and associated factors (2013 - 2023). [PDF]

open access: yesFront Cell Infect Microbiol
Teumezgi HA   +7 more
europepmc   +1 more source

Alarming levels of fluoroquinolone resistance among MDR-TB patients in Poland: molecular and phenotypic analysis. [PDF]

open access: yesFront Cell Infect Microbiol
Kozińska M   +4 more
europepmc   +1 more source

XDR TB [PDF]

open access: yes
Extensively drug resistant TB (XDR TB) is a rare type of multidrug-resistant tuberculosis (MDR TB) that is resistant to isoniazid and rifampin, plus any fluoroquinolone and at least one of three injectable second-line drugs (i.e., amikacin, kanamycin, or

core  

Comments on "Tuberculosis infection control in MDR-TB designated hospitals in Jiangsu Province, China". [PDF]

open access: yesJ Clin Tuberc Other Mycobact Dis
Katkuri SN   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy